title: Inherently multimodal nanoparticle-driven tracking and real-time delineation of orthotopic prostate tumors and micrometastases.
abstract: Prostate cancer is the most common cancer among men and the second cause of male cancer-related deaths. There are currently three critical needs in prostate cancer imaging to personalize cancer treatment: (1) accurate intraprostatic imaging for multiple foci and extra-capsular extent; (2) monitoring local and systemic treatment response and predicting recurrence; and (3) more sensitive imaging of occult prostate cancer bone metastases. Recently, our lab developed porphysomes, inherently multimodal, all-organic nanoparticles with flexible and robust radiochemistry. Herein, we validate the first in vivo application of (64)Cu-porphysomes in clinically relevant orthotopic prostate and bony metastatic cancer models. We demonstrate clear multimodal delineation of orthotopic tumors on both the macro- and the microscopic scales (using both PET and fluorescence) and sensitively detected small bony metastases (<2 mm). The unique and multifaceted properties of porphysomes offers a promising all-in-one prostate cancer imaging agent for tumor detection and treatment response/recurrence monitoring using both radionuclide- and photonic-based strategies.
authors.affiliation: Ontario Cancer Institute, Campbell Family Institute for Cancer Research and Techna Institute, UHN, 610 University Avenue, Toronto, ON Canada M5G 2M9.
authors.forename: Tracy W
authors.initials: TW
authors.lastname: Liu
authors.forename: Thomas D
authors.initials: TD
authors.lastname: Macdonald
authors.forename: Cheng S
authors.initials: CS
authors.lastname: Jin
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Gold
authors.forename: Robert G
authors.initials: RG
authors.lastname: Bristow
authors.forename: Brian C
authors.initials: BC
authors.lastname: Wilson
authors.forename: Gang
authors.initials: G
authors.lastname: Zheng
mesh_terms: D000818:Animals; D001692:Biological Transport; D045744:Cell Line, Tumor; D003301:Copper Radioisotopes; D006801:Humans; D008051:Lipid Bilayers / Q000737:chemistry; D008297:Male; D051379:Mice; D008819:Mice, Nude; D064847:Multimodal Imaging; D053758:Nanoparticles / Q000737:chemistry*; D061206:Neoplasm Micrometastasis / Q000000981:diagnostic imaging*; D011166:Porphyrins / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology*; D013997:Time Factors; D014057:Tomography, X-Ray Computed
chemical_list: D003301:Copper Radioisotopes; D008051:Lipid Bilayers; D011166:Porphyrins
references.citation: Cancer. 1997 Oct 15;80(8 Suppl):1595-607
references.pmid: 9362427
references.citation: N Engl J Med. 2009 Mar 26;360(13):1320-8
references.pmid: 19297566
references.citation: N Engl J Med. 2011 Nov 24;365(21):2013-9
references.pmid: 22029754
references.citation: Acc Chem Res. 2011 Oct 18;44(10):1050-60
references.pmid: 21919457
references.citation: Science. 1951 May 4;113(2940):525-7
references.pmid: 14828392
references.citation: Mol Imaging. 2009 Jan-Feb;8(1):15-26
references.pmid: 19344572
references.citation: Prog Clin Biol Res. 1984;170:629-36
references.pmid: 6241702
references.citation: Clin Cancer Res. 2008 May 15;14(10):3036-43
references.pmid: 18483369
references.citation: Theranostics. 2011;1:354-62
references.pmid: 21938263
references.citation: Radiology. 1993 Jan;186(1):153-7
references.pmid: 8416557
references.citation: Anal Chem. 2011 Apr 15;83(8):2877-82
references.pmid: 21413785
references.citation: Angew Chem Int Ed Engl. 2012 Mar 5;51(10):2429-33
references.pmid: 22267090
references.citation: Nat Rev Cancer. 2002 Sep;2(9):683-93
references.pmid: 12209157
references.citation: Med Princ Pract. 2011;20(5):397-415
references.pmid: 21757928
references.citation: J Clin Oncol. 2011 Sep 20;29(27):3669-76
references.pmid: 21825257
references.citation: ACS Nano. 2012 Aug 28;6(8):6843-51
references.pmid: 22702416
references.citation: Theranostics. 2011;1:363-70
references.pmid: 21938264
references.citation: Magn Reson Med. 2001 Dec;46(6):1054-8
references.pmid: 11746568
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Eur Radiol. 2007 Apr;17(4):939-49
references.pmid: 16951929
references.citation: Anal Bioanal Chem. 2008 Aug;391(7):2469-95
references.pmid: 18548237
references.citation: Nat Rev Drug Discov. 2008 Sep;7(9):771-82
references.pmid: 18758474
references.citation: Curr Urol Rep. 2012 Jun;13(3):195-201
references.pmid: 22430278
references.citation: Hum Pathol. 1993 Feb;24(2):220-6
references.pmid: 8432518
references.citation: Chem Rev. 2010 May 12;110(5):3146-95
references.pmid: 20225900
references.citation: N Engl J Med. 2008 Mar 20;358(12):1250-61
references.pmid: 18354103
references.citation: Nat Biotechnol. 2005 Mar;23(3):313-20
references.pmid: 15765087
references.citation: Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
references.pmid: 2946403
references.citation: Curr Opin Urol. 2012 Mar;22(2):109-20
references.pmid: 22262249
references.citation: Nature. 2008 Apr 3;452(7187):580-9
references.pmid: 18385732
references.citation: Angew Chem Int Ed Engl. 2012 Dec 21;51(52):13128-31
references.pmid: 23154923
references.citation: Cancer. 1958 Mar-Apr;11(2):259-63
references.pmid: 13511344
references.citation: ACS Nano. 2013 Mar 26;7(3):2541-50
references.pmid: 23394589
references.citation: J Urol. 2009 Oct;182(4):1371-7
references.pmid: 19683262
references.citation: J Urol. 2011 Apr;185(4):1246-54
references.pmid: 21334018
references.citation: Eur J Cancer. 2005 Apr;41(6):932-40
references.pmid: 15808959
references.citation: Acc Chem Res. 2011 Oct 18;44(10):969-78
references.pmid: 21675721
references.citation: Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013 May-Jun;5(3):250-65
references.pmid: 23450626
references.citation: Bioconjug Chem. 2007 Mar-Apr;18(2):389-96
references.pmid: 17263568
references.citation: AJR Am J Roentgenol. 2002 Apr;178(4):915-9
references.pmid: 11906872
references.citation: Cancer. 2011 Mar 15;117(6):1123-35
references.pmid: 20960523
references.citation: Cancer Treat Rev. 2003 Jun;29(3):189-98
references.pmid: 12787713
references.citation: Curr Opin Urol. 2008 Jan;18(1):71-7
references.pmid: 18090494
references.citation: J Med Chem. 2010 Jul 22;53(14):5333-41
references.pmid: 20568777
references.citation: BJU Int. 2012 Jul;110(1):50-5
references.pmid: 22077660
references.citation: Eur Urol. 2005 Oct;48(4):546-51
references.pmid: 16046052
references.citation: Eur Radiol. 2010 May;20(5):1254-66
references.pmid: 19921202
references.citation: AJR Am J Roentgenol. 1989 Jan;152(1):167-73
references.pmid: 2783272
references.citation: Bioconjug Chem. 2011 Jun 15;22(6):1021-30
references.pmid: 21585206
references.citation: Nat Rev Urol. 2010 Oct;7(10):562-71
references.pmid: 20842187
references.citation: Nanomedicine (Lond). 2008 Oct;3(5):703-17
references.pmid: 18817471
references.citation: Cancer. 1997 Oct 15;80(8 Suppl):1546-56
references.pmid: 9362421
references.citation: J Clin Oncol. 2002 Jan 15;20(2):557-66
references.pmid: 11786586
references.citation: Prostate. 2006 Aug 1;66(11):1213-22
references.pmid: 16683269
references.citation: Med Res Rev. 2013 Jan;33(1):3-32
references.pmid: 23239045
references.citation: Nat Rev Urol. 2009 Apr;6(4):191-203
references.pmid: 19352394
references.citation: Prostate. 1999 May 15;39(3):198-204
references.pmid: 10334109
references.citation: Curr Opin Urol. 2012 Mar;22(2):104-8
references.pmid: 22273756
references.citation: Nat Mater. 2011 Apr;10(4):324-32
references.pmid: 21423187
references.citation: Future Oncol. 2011 Jun;7(6):775-87
references.pmid: 21675840
references.citation: J Nucl Med. 1993 Dec;34(12):2191-8
references.pmid: 8254410
references.citation: J Endourol. 2006 Sep;20(9):688-92
references.pmid: 16999628
references.citation: Surgery. 2011 May;149(5):689-98
references.pmid: 21496565
references.citation: ACS Nano. 2013 Apr 23;7(4):3484-90
references.pmid: 23464857